HALOZYME THERAPEUTICS, INC.
HALOAPI behind this page
HALO FY 2025 request
Playground key active
/api/financials?ticker=HALO&year=2025&quarter=4&full_year_mode=true
Pick an endpoint and run the request.Income Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Revenue | 1,396,611 | 1,015,324 | +37.6% |
Show Product Lines breakouts |
|||
| Bulk rHuPH20 sales | 133,023 | 86,334 | +54.1% |
| Device licensing and development revenue | 16,856 | 11,341 | +48.6% |
| Device partnered product sales | 48,813 | 50,538 | -3.4% |
| Event-based development and regulatory milestones and other fees | 47 | 72,500 | -99.9% |
| Product | 376,444 | 303,492 | +24.0% |
| Proprietary product sales | 194,608 | 166,620 | +16.8% |
| Revenues under collaborative agreements | 152,327 | 140,841 | +8.2% |
| Royalty | 867,840 | 570,991 | +52.0% |
| Sales-based milestones | 70,000 | 30,000 | +133.3% |
| Upfront license and target nomination fees | 18,471 | 27,000 | -31.6% |
Show Geography breakouts |
|||
| All other foreign · Geographic Concentration Risk | 33,334 | 9,528 | +249.9% |
| BE · Geographic Concentration Risk | 217,516 | 84,005 | +158.9% |
| CH · Geographic Concentration Risk | 276,414 | 212,391 | +30.1% |
| JP · Geographic Concentration Risk | 46,372 | 18,939 | +144.8% |
| US · Geographic Concentration Risk | 822,975 | 690,461 | +19.2% |
Show Concentration Risk By Type breakouts |
|||
| Geographic Concentration Risk | 1,396,611 | 1,015,324 | +37.6% |
| Cost of Revenue | 228,774 | 159,417 | +43.5% |
| Amortization Of Intangible Assets | 76,662 | 71,049 | +7.9% |
| Research And Development Expense Excluding Acquired In Process Cost | 81,490 | 79,048 | +3.1% |
| Selling, General & Administrative | 207,092 | 154,335 | +34.2% |
| Impairment Of Intangible Assets Excluding Goodwill | 48,700 | — | — |
| Research And Development Asset Acquired Other Than Through Business Combination Written Off | 284,887 | — | — |
| Total Costs & Expenses | 927,605 | 463,849 | +100.0% |
| Operating Income | 469,006 | 551,475 | -15.0% |
| Other Non-Operating Income (Expense) | 21,472 | 23,752 | -9.6% |
| Induced Conversion Of Convertible Debt Expense | -5,477 | — | — |
| Interest Expense | -18,126 | -18,095 | -0.2% |
| Income Before Taxes | 466,875 | 557,132 | -16.2% |
| Income Tax Expense (Benefit) | 149,986 | 113,041 | +32.7% |
| Net Income | 316,889 | 444,091 | -28.6% |
Show Equity Components breakouts |
|||
| Retained Earnings | 316,889 | 444,091 | -28.6% |
| EPS (Basic) | 2.64 | 3.5 | -24.6% |
| EPS (Diluted) | 2.56 | 3.43 | -25.4% |
| Wtd Avg Shares (Basic) | 119,840 | 126,827 | -5.5% |
| Wtd Avg Shares (Diluted) | 123,904 | 129,424 | -4.3% |
| Comprehensive Income | 294,968 | 457,198 | -35.5% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax | 6,502 | -1,224 | +631.2% |
Balance Sheet
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 133,820 | 115,850 | +15.5% |
| Debt Securities Available For Sale Excluding Accrued Interest Current | 9,000 | 480,224 | -98.1% |
| Accounts Receivable And Contract With Customer Asset After Allowance For Credit Loss Current | 441,273 | 308,455 | +43.1% |
| Inventory | 176,475 | 141,860 | +24.4% |
| Prepaid Expenses & Other Current Assets | 64,639 | 38,951 | +65.9% |
| Total Current Assets | 825,207 | 1,085,340 | -24.0% |
| Accounts Receivable | 426,273 | 288,204 | +47.9% |
| Non-Current Assets | |||
| Prepaid Expense And Other Assets Noncurrent | 53,551 | 80,596 | -33.6% |
| Goodwill | 580,360 | 416,821 | +39.2% |
| Restricted Cash And Cash Equivalents Noncurrent | 2,601 | — | — |
| Total Assets | 2,525,323 | 2,063,477 | +22.4% |
| Property, Plant & Equipment | 44,442 | 40,864 | +8.8% |
| Operating Lease Right-of-Use Assets | 37,695 | 34,171 | +10.3% |
| Intangible Assets | 981,467 | 353,130 | +177.9% |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Auto Injector Technology Platform [Member] | 194,979 | 252,408 | -22.8% |
| Customer Relationships | 466,257 | — | — |
| Hypercon developed technology platform | 228,169 | — | — |
| Trade Names | 4,960 | — | — |
| XYOSTED Proprietary Product [Member] | 87,102 | 100,722 | -13.5% |
| Other Assets | |||
| Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 82,137 | 75,035 | +9.5% |
| Intangible Assets Net Excluding Goodwill | 981,467 | 401,830 | +144.2% |
| Current Liabilities | |||
| Accounts Payable | 20,899 | 10,249 | +103.9% |
| Accrued Liabilities | 156,193 | 128,851 | +21.2% |
| Total Current Liabilities | 177,092 | 139,100 | +27.3% |
| Non-Current Liabilities | |||
| Long-Term Debt | 2,142,630 | 1,505,798 | +42.3% |
| Other Non-Current Liabilities | 113,863 | 54,758 | +107.9% |
| Deferred Tax Liabilities | 42,924 | — | — |
| Total Liabilities | 2,476,509 | 1,699,656 | +45.7% |
| Long-Term Debt | 2,142,630 | 1,505,798 | +42.3% |
Show Debt Instrument breakouts |
|||
| 2027 Convertible Notes | 208,517 | 797,482 | -73.9% |
| 2028 Convertible Notes | 464,438 | 708,316 | -34.4% |
| 2031 Convertible Notes | 734,892 | — | — |
| 2032 Convertible Notes | 734,783 | — | — |
| Stockholders' Equity | |||
| Common Stock | 118 | 123 | -4.1% |
| Additional Paid In Capital Common Stock | 12,002 | — | — |
| Accumulated Other Comprehensive Income | -18,092 | 3,829 | -572.5% |
| Retained Earnings | 54,786 | 359,869 | -84.8% |
| Total Stockholders' Equity | 48,814 | 363,821 | -86.6% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -18,092 | 3,829 | -572.5% |
| Additional Paid In Capital | 12,002 | — | — |
| Common Stock | 118 | 123 | -4.1% |
| Retained Earnings | 54,786 | 359,869 | -84.8% |
| Total Liabilities & Equity | 2,525,323 | 2,063,477 | +22.4% |
Cash Flow Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Stock-Based Compensation | 51,565 | 43,385 | +18.9% |
| Depreciation & Amortization | 11,389 | 10,263 | +11.0% |
| Amortization Of Debt Discount Premium | 7,506 | 7,350 | +2.1% |
Show Debt Instrument breakouts |
|||
| 2027 Convertible Notes · Convertible Debt | 3,029 | 3,432 | -11.7% |
| 2028 Convertible Notes · Convertible Debt | 2,980 | 3,118 | -4.4% |
| 2031 Convertible Notes · Convertible Debt | 397 | — | — |
| 2032 Convertible Notes · Convertible Debt | 289 | — | — |
Show Long-Term Debt Type breakouts |
|||
| Convertible Debt | 6,695 | 6,550 | +2.2% |
| Accretion Amortization Of Discounts And Premiums Investments | -3,296 | -10,918 | +69.8% |
| Debt Securities Available For Sale Realized Gain Loss | -171 | -7 | -2342.9% |
| Gain Loss On Sale Of Property Plant Equipment | 2,621 | 1,529 | +71.4% |
| Deferred Rent Payments | 951 | 1,067 | -10.9% |
| Increase Decrease In Deferred Income Taxes | 634 | 532 | +19.2% |
| Change in Accounts Receivable | -128,063 | -74,245 | -72.5% |
| Change in Inventory | 2,554 | -67,381 | +103.8% |
| Change in Prepaid & Other Assets | -32,958 | 5,356 | -715.3% |
| Increase Decrease In Accounts Payable And Accrued Liabilities | 6,211 | 46,993 | -86.8% |
| Net Cash from Operations | 651,558 | 479,064 | +36.0% |
| Investing Activities | |||
| Purchases of Investments | -247,355 | -647,601 | +61.8% |
| Proceeds From Sale And Maturity Of Available For Sale Securities | 722,248 | 395,574 | +82.6% |
| Payments To Acquire Businesses Net Of Cash Acquired | -725,965 | — | — |
| Payment To Acquire In Process Research And Development Net Of Cash Acquired | -287,771 | — | — |
| Capital Expenditures | -6,970 | -10,696 | +34.8% |
| Net Cash from Investing | -545,813 | -262,723 | -107.8% |
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | 410 | 3,078 | -86.7% |
| Financing Activities | |||
| Repayments Of Convertible Debt (FY) | — | — | — |
Show Debt Instrument breakouts |
|||
| 2027 Convertible Notes | -595,425 | — | — |
| 2028 Convertible Notes | -250,001 | — | — |
| Proceeds From Convertible Debt (FY) | — | — | — |
Show Debt Instrument breakouts |
|||
| 2031 Convertible Notes | 735,000 | — | — |
| 2032 Convertible Notes | 735,000 | — | — |
| Payment For Induced Conversion Of Convertible Debt | -5,477 | — | — |
| Payments Of Debt Extinguishment Costs (FY) | — | — | — |
Show Debt Instrument breakouts |
|||
| 2027 Convertible Notes | -78,132 | — | — |
| 2028 Convertible Notes | -89,833 | — | — |
| Payment For Capped Call Transactions (FY) | — | — | — |
Show Debt Instrument breakouts |
|||
| 2031 Convertible Notes | -104,025 | — | — |
| 2032 Convertible Notes | -106,800 | — | — |
| Debt Issuance Costs | -4,938 | — | — |
| Share Repurchases | -342,372 | -250,000 | -36.9% |
| Proceeds From Payments For Issuance Of Shares Share Based Payment Arrangement Including Option Exercised | 21,829 | 31,139 | -29.9% |
| Net Cash from Financing | -85,174 | -218,861 | +61.1% |
| Supplemental | |||
| Interest Paid | 11,429 | 10,565 | +8.2% |
| Income Taxes Paid | 134,641 | 80,618 | +67.0% |
| Unpaid Capital Expenditures | 902 | 280 | +222.1% |
| Other Cash Flow | |||
| Net Change in Cash | 20,571 | -2,520 | +916.3% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 136,421 | 115,850 | +17.8% |
Values in thousands USD. Source: SEC EDGAR 10-K filing.